Literature DB >> 2828948

The risk of zoster after varicella vaccination in children with leukemia.

R Lawrence1, A A Gershon, R Holzman, S P Steinberg.   

Abstract

We examined the incidence of zoster in 346 children with underlying acute lymphoblastic leukemia who were immunized with live attenuated varicella vaccine while in remission. We also compared a subset of 84 of these children with a matched group of 84 children with leukemia who had had natural infection with varicella. Of the 346 vaccinated children, 5 (1.45 percent) became infected with zoster after 10,878 months of observation, for an incidence of 0.552 case per 100 person-years. Among the matched pairs of subjects, zoster occurred in 3 (3.6 percent) of the 84 vaccinated subjects during 2936 months of observation--an incidence of 1.23 cases per 100 person-years--and in 11 (13.1 percent) of the subjects with natural infection during 4245 months--an incidence of 3.11 cases of zoster per 100 person-years. Although the incidence of zoster was more than twice as high in the control children as in the vaccinated children (3.11 vs. 1.23 cases per 100 person-years), a Kaplan-Meier product-limit analysis revealed no significant differences in incidence between the two groups. Children from both groups in whom leukemia recurred were more likely to contract zoster than those who did not have a recurrence (7 of 35 vs. 7 of 133, P less than 0.025). Zoster was not a marker for impending relapse. No case of zoster was severe or disseminated. We conclude that the incidence of zoster following immunization with live attenuated varicella vaccine is no greater than that following natural varicella infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828948     DOI: 10.1056/NEJM198803033180904

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

Review 1.  Sleep in Parkinson's disease.

Authors:  Ambra Stefani; Birgit Högl
Journal:  Neuropsychopharmacology       Date:  2019-06-24       Impact factor: 7.853

Review 2.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

3.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

4.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

5.  The use of varicella vaccine in Britain.

Authors:  H O Kangro; R B Heath
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-23

6.  Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

Authors:  Joanne F Chou; Nancy A Kernan; Susan Prockop; Glenn Heller; Andromachi Scaradavou; Rachel Kobos; Molly A Knowles; Esperanza B Papadopoulos; Anne Casson; Catherine Copeland; Joanne Torok-Castanza; Nicole Zakak; Julianne Ruggiero; Trudy N Small
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-23       Impact factor: 5.742

Review 7.  Supportive therapy in management of leukemias.

Authors:  V P Choudhry; N Desai
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

8.  Age-specific incidence of chickenpox.

Authors:  R Finger; J P Hughes; B J Meade; A R Pelletier; C T Palmer
Journal:  Public Health Rep       Date:  1994 Nov-Dec       Impact factor: 2.792

9.  In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.

Authors:  J R McKolanis; A H Ragab; D S Schmid
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

Review 10.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.